Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Encorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | PGRMC1 | O00264 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | PCYT1A | P49585 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Encorafenib SCHEMBL8512458 | 1.00 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL31210316 | 1.00 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL8231398 | 1.00 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL29368575 | 1.00 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL23802720 | 0.95 | BRAF (0.91) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL31098916 | 0.95 | BRAF (0.91) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL8236124 | 0.93 | BRAF (0.87) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL8236122 | 0.93 | BRAF (0.87) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL8240787 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL20532264 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5070 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146289-A1 | ASSESSING AND TREATING MELANOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-05-28 | — | — | US | claimed |
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735598-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | Christiana Care Gene Editing Institute, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20150133478-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-05-14 | — | — | US | claimed |
| EP-2831589-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2015-02-04 | — | — | EP | claimed |
| EP-2470526-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2014-05-28 | — | — | EP | claimed |
| EP-2727918-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2014-05-07 | — | — | EP | claimed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | claimed |
| WO-2013148100-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-10-03 | — | — | WO | claimed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | claimed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | claimed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | claimed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | claimed |